JP5491724B2 - 生物学的利用能を向上した医薬組成物 - Google Patents

生物学的利用能を向上した医薬組成物 Download PDF

Info

Publication number
JP5491724B2
JP5491724B2 JP2008298513A JP2008298513A JP5491724B2 JP 5491724 B2 JP5491724 B2 JP 5491724B2 JP 2008298513 A JP2008298513 A JP 2008298513A JP 2008298513 A JP2008298513 A JP 2008298513A JP 5491724 B2 JP5491724 B2 JP 5491724B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
drug
present
composition
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008298513A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009132712A5 (enExample
JP2009132712A (ja
Inventor
ハオ ウェイ−ファ
ワン ジョン−ジン
スー チャン−シャン
Original Assignee
イノファーマックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イノファーマックス インコーポレイテッド filed Critical イノファーマックス インコーポレイテッド
Publication of JP2009132712A publication Critical patent/JP2009132712A/ja
Publication of JP2009132712A5 publication Critical patent/JP2009132712A5/ja
Application granted granted Critical
Publication of JP5491724B2 publication Critical patent/JP5491724B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2008298513A 2007-11-21 2008-11-21 生物学的利用能を向上した医薬組成物 Expired - Fee Related JP5491724B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/944,239 2007-11-21
US11/944,239 US20090130198A1 (en) 2007-11-21 2007-11-21 Pharmaceutical composition with enhanced bioavailability

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014038075A Division JP2014098039A (ja) 2007-11-21 2014-02-28 生物学的利用能を向上した医薬組成物

Publications (3)

Publication Number Publication Date
JP2009132712A JP2009132712A (ja) 2009-06-18
JP2009132712A5 JP2009132712A5 (enExample) 2011-11-10
JP5491724B2 true JP5491724B2 (ja) 2014-05-14

Family

ID=40439733

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008298513A Expired - Fee Related JP5491724B2 (ja) 2007-11-21 2008-11-21 生物学的利用能を向上した医薬組成物
JP2014038075A Pending JP2014098039A (ja) 2007-11-21 2014-02-28 生物学的利用能を向上した医薬組成物
JP2016053870A Pending JP2016106152A (ja) 2007-11-21 2016-03-17 生物学的利用能を向上した医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014038075A Pending JP2014098039A (ja) 2007-11-21 2014-02-28 生物学的利用能を向上した医薬組成物
JP2016053870A Pending JP2016106152A (ja) 2007-11-21 2016-03-17 生物学的利用能を向上した医薬組成物

Country Status (5)

Country Link
US (1) US20090130198A1 (enExample)
EP (1) EP2062571B8 (enExample)
JP (3) JP5491724B2 (enExample)
CN (1) CN101439015B (enExample)
ES (1) ES2396723T3 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017204210A1 (ja) 2016-05-24 2017-11-30 三生医薬株式会社 経口医薬組成物及び該組成物からなる粒子状製剤の製造方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ592970A (en) * 2008-12-03 2013-05-31 Astellas Deutschland Gmbh Oral dosage forms of bendamustine
DK2519261T3 (da) 2009-12-28 2014-02-03 Reig Jofre S A Lab Flydende oralt farmaceutisk præparat, som er en opløsning omfattende nifedipin.
SG10201503234SA (en) 2010-05-03 2015-06-29 Teikoku Pharma Usa Inc Non-Aqueous Taxane Pro-Emulsion Formulations and Methods of Making and Using the Same
MY158809A (en) * 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
CN102389401B (zh) * 2011-11-22 2013-05-22 陆荣政 一种右旋布洛芬颗粒及其制备方法
KR101211902B1 (ko) * 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CN109953954A (zh) 2013-08-27 2019-07-02 V·沃道里斯 苯达莫司汀医药组合物
RU2746548C2 (ru) * 2014-11-04 2021-04-15 Иннофармакс, Инк. Пероральное введение неустойчивых или плохо всасывающихся лекарственных средств
EP3337463A4 (en) * 2015-08-19 2019-04-03 Vivus, Inc. PHARMACEUTICAL FORMULATIONS
JP2020152674A (ja) * 2019-03-20 2020-09-24 株式会社リコー 難水溶性化合物の可溶化物の製造方法
KR102676428B1 (ko) * 2019-07-08 2024-06-19 가부시키가이샤 모레스코 마이크로에멀션을 조제하기 위한 조성물, 마이크로에멀션, 이들의 제조 방법, 및 마이크로에멀션의 이용

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8630273D0 (en) * 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
AU1766592A (en) * 1991-06-03 1993-01-08 Merck Sharp & Dohme Limited Pharmaceutical formulations of a benzodiazepine
US6312704B1 (en) * 1993-09-30 2001-11-06 Gattefosse, S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US5965160A (en) * 1995-04-24 1999-10-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Self-emulsifiable formulation producing an oil-in-water emulsion
JP3009742B2 (ja) * 1995-08-25 2000-02-14 サングスタット メディカル コーポレイション 経口用シクロスポリン製剤
KR970064620A (ko) * 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
KR20040004416A (ko) * 1997-01-30 2004-01-13 노파르티스 아게 오일을 함유하지 않은 사이클로스포린 ａ 함유 제약 조성물
NZ337316A (en) * 1997-03-12 2001-06-29 Abbott Lab Hydrophilic binary systems comprising cyclosporine, hydrophilic phase and a surfactant for the administration of cyclosporine
ID25908A (id) * 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
AU3843999A (en) * 1998-05-07 1999-11-23 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
DE69822814T2 (de) * 1998-08-18 2005-01-27 Panacea Biotec Ltd. Zusammensetzung enthaltend Cyclosporin in einem hydrophilen Träger
CN1236813C (zh) * 1998-12-11 2006-01-18 药品处理公司 水难溶性药物的自乳化组合物
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
US6596306B1 (en) * 2000-07-07 2003-07-22 David Ho Sue San Ho Drug delivery system:formulation for fat-soluble drugs
DE10133305B4 (de) * 2001-07-12 2004-06-03 Aquanova German Solubilisate Technologies (Agt) Gmbh Ubichinon Konzentrat
US6960563B2 (en) * 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
JP2005343799A (ja) * 2004-05-31 2005-12-15 Nisshin Oillio Group Ltd 水分散性植物ステロース製剤と油脂含有水分散性植物ステロール製剤
KR100678829B1 (ko) * 2004-12-06 2007-02-05 한미약품 주식회사 타크로리무스의 경구용 마이크로에멀젼 조성물

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017204210A1 (ja) 2016-05-24 2017-11-30 三生医薬株式会社 経口医薬組成物及び該組成物からなる粒子状製剤の製造方法
EP4279137A2 (en) 2016-05-24 2023-11-22 Sunsho Pharmaceutical Co., Ltd. Oral pharmaceutical composition and method for producing particulate formulation comprising composition

Also Published As

Publication number Publication date
ES2396723T3 (es) 2013-02-25
US20090130198A1 (en) 2009-05-21
EP2062571B1 (en) 2012-11-14
CN101439015B (zh) 2013-02-13
CN101439015A (zh) 2009-05-27
JP2016106152A (ja) 2016-06-16
EP2062571A1 (en) 2009-05-27
EP2062571B8 (en) 2012-12-19
JP2014098039A (ja) 2014-05-29
JP2009132712A (ja) 2009-06-18

Similar Documents

Publication Publication Date Title
JP5491724B2 (ja) 生物学的利用能を向上した医薬組成物
JP5753157B2 (ja) 親水性薬剤の自己マイクロエマルジョン化経口医薬組成物およびその調製方法
Talegaonkar et al. Microemulsions: a novel approach to enhanced drug delivery
CN101862306B (zh) 新型难溶性药物口服固体自乳化制剂及其制备方法
Zhang et al. Preparation and evaluation of self-microemulsifying drug delivery system of oridonin
JP4695260B2 (ja) 抗癌組成物
CN104411299B (zh) 消旋卡多曲类脂组合物
JP2019514995A (ja) グリセリン脂肪酸エステル誘導体又はプロピレングリコール脂肪酸エステル誘導体を含むデュタステリド及びタダラフィルの複合製剤並びにそれを含む経口用カプセル製剤
McConville et al. Development and characterisation of a self-microemulsifying drug delivery systems (SMEDDSs) for the vaginal administration of the antiretroviral UC-781
ES2210056T3 (es) Preconcentrados en microemulsion y microemulsiones que contienen coenzima q10.
CN101780037B (zh) 双嘧达莫自乳化给药系统及其制备方法
HUP0300539A2 (hu) Új emulzió előkoncentrátum formájú gyógyszerkészítmény
BRPI0815110B1 (pt) Sistemas de distribuição para solubilização de ingredientes farmaceuticamente ativos insolúveis em água
US20120213855A1 (en) Dosage forms for weakly ionizable compounds
WO2010030667A2 (en) Dosage forms for weakly ionizable compounds
CA2443461A1 (en) Pharmaceutical formulations containing anti-inflammatory active ingredients and the use of said formulations
Reddy et al. Review on self micro emulsifying drug delivery systems
Carli et al. Ubidecarenone nanoemulsified composite systems
STRICKLEY et al. Solubilizing vehicles for oral formulation development
KR20020042218A (ko) 자가미세유화형 약물전달시스템을 이용한 고지혈증치료용약제 조성물
KR100524700B1 (ko) 자가미세유화형 약물전달시스템을 이용한 고지혈증치료용약제 조성물
TWI354570B (en) Pharmaceutical composition with enhanced bioavaila
KR100449818B1 (ko) 가용화 기법인 ｓｍｅｄｄｓ를 이용한 이부프로펜의연질캅셀제 및 주사제
Kushawah et al. LIPID BASED NANOEMULSIONS AS DRUG DELIVERY SYSTEM FOR POORLY-WATER SOLUBLE DRUG
JP2004519489A (ja) 薬剤組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110928

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130820

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130918

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131018

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140228

R150 Certificate of patent or registration of utility model

Ref document number: 5491724

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees